Windtree Therapeutics Files 8-K on Security Holder Vote Matters

TL;DR

Windtree Therapeutics (WINT) filed an 8-K today regarding a vote by security holders. Keep an eye on the outcome.

AI Summary

On April 10, 2024, Windtree Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as Discovery Laboratories Inc. and Ansan Pharmaceuticals Inc., is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing indicates that Windtree Therapeutics is engaging its security holders in important corporate decisions, which could impact the company's future direction and shareholder value.

Risk Assessment

Risk Level: medium — Filings related to security holder votes can signal significant corporate events or potential changes that may affect the company's stock price.

Key Numbers

• 001-39290 — Commission File Number (Identifies the company's SEC filing history)
• 94-3171943 — I.R.S. Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Windtree Therapeutics, Inc. (company) — Registrant
• Discovery Laboratories Inc. /DE/ (company) — Former company name
• Ansan Pharmaceuticals Inc (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (address) — Principal executive office address

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma

Filing Documents

• wint20240410_8k.htm (8-K) — 28KB
• 0001437749-24-011646.txt ( ) — 156KB
• wint-20240410.xsd (EX-101.SCH) — 3KB
• wint-20240410_def.xml (EX-101.DEF) — 11KB
• wint-20240410_lab.xml (EX-101.LAB) — 15KB
• wint-20240410_pre.xml (EX-101.PRE) — 11KB
• wint20240410_8k_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On April 10, 2024, Windtree Therapeutics, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") where the Company's stockholders voted on and approved an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Charter"), to effect a reverse stock split of the Company's outstanding shares of common stock, par value $0.001 per share (the "Common Stock") by a ratio of any whole number between 1-for-5 and 1-for-25, the implementation and timing of which shall be subject to the discretion of the Company's Board of Directors (the "Reverse Stock Split"). The following is a brief description of the final voting results from the Special Meeting. Proposal 1 – Reverse Stock Split . The Reverse Stock Split was approved, as follows: Votes For Votes Against Abstentions 3,225,151 1,819,203 13,921

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: April 10, 2024 Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR